[go: up one dir, main page]

AU6053496A - The use of sertraline to treat post myocardial infarction patients - Google Patents

The use of sertraline to treat post myocardial infarction patients

Info

Publication number
AU6053496A
AU6053496A AU60534/96A AU6053496A AU6053496A AU 6053496 A AU6053496 A AU 6053496A AU 60534/96 A AU60534/96 A AU 60534/96A AU 6053496 A AU6053496 A AU 6053496A AU 6053496 A AU6053496 A AU 6053496A
Authority
AU
Australia
Prior art keywords
sertraline
myocardial infarction
post myocardial
infarction patients
treat post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU60534/96A
Other versions
AU721967B2 (en
Inventor
Brian F. Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU6053496A publication Critical patent/AU6053496A/en
Application granted granted Critical
Publication of AU721967B2 publication Critical patent/AU721967B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method of treating post myocardial infarction human patients comprising administering to such patients the compound (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthal enamine, also known by the generic name sertraline, or a pharmaceutically acceptable salt thereof.
AU60534/96A 1995-07-17 1996-07-16 The use of sertraline to treat post myocardial infarction patients Ceased AU721967B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US143795P 1995-07-17 1995-07-17
US1437 1995-07-17

Publications (2)

Publication Number Publication Date
AU6053496A true AU6053496A (en) 1997-01-23
AU721967B2 AU721967B2 (en) 2000-07-20

Family

ID=21696010

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60534/96A Ceased AU721967B2 (en) 1995-07-17 1996-07-16 The use of sertraline to treat post myocardial infarction patients

Country Status (15)

Country Link
EP (1) EP0768083B1 (en)
JP (1) JPH0930959A (en)
KR (1) KR970005283A (en)
CN (1) CN1147937A (en)
AT (1) ATE235237T1 (en)
AU (1) AU721967B2 (en)
CA (1) CA2181225C (en)
DE (1) DE69626916T2 (en)
DK (1) DK0768083T3 (en)
ES (1) ES2192217T3 (en)
IL (1) IL118833A (en)
MY (1) MY117638A (en)
NZ (1) NZ299006A (en)
PT (1) PT768083E (en)
ZA (1) ZA966027B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1261792A (en) * 1997-07-01 2000-08-02 辉瑞产品公司 Gelatine encapsulated solution dosage forms of sertraline
ID23503A (en) 1997-07-01 2000-04-27 Pfizer SERTRALINA SALES AND DETAILED FORMS OF SERTRALINA
GB9714841D0 (en) * 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
US6727283B2 (en) * 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
AP2001002119A0 (en) * 1998-10-13 2001-03-22 Pfizer Prod Inc Sertraline oral concentrate.
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
GB0814466D0 (en) * 2008-08-07 2008-09-10 Rosemont Pharmaceuticals Ltd Sertraline composition
US20220265579A1 (en) * 2019-05-15 2022-08-25 Vasthera Co. Ltd. Composition for preventing or treating cardio-cerebrovascular disease comprising autophagy activator as active ingredient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms

Also Published As

Publication number Publication date
CA2181225A1 (en) 1997-01-18
DE69626916T2 (en) 2003-10-09
EP0768083B1 (en) 2003-03-26
IL118833A0 (en) 1996-10-31
EP0768083A3 (en) 1999-12-01
PT768083E (en) 2003-08-29
AU721967B2 (en) 2000-07-20
DK0768083T3 (en) 2003-06-23
NZ299006A (en) 2000-08-25
CA2181225C (en) 1999-03-23
ZA966027B (en) 1998-01-16
ES2192217T3 (en) 2003-10-01
MY117638A (en) 2004-07-31
ATE235237T1 (en) 2003-04-15
CN1147937A (en) 1997-04-23
DE69626916D1 (en) 2003-04-30
JPH0930959A (en) 1997-02-04
IL118833A (en) 2000-07-26
EP0768083A2 (en) 1997-04-16
KR970005283A (en) 1997-02-19

Similar Documents

Publication Publication Date Title
AU609664B1 (en) A method of treating premature ejaculation using sertraline
EP0703785B8 (en) Methods for treating muscle diseases and disorders
CA2029065A1 (en) Method of treating anxiety related disorders using sertraline
AU6053496A (en) The use of sertraline to treat post myocardial infarction patients
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
CA2167257A1 (en) Use of Sertraline to Treat Cancer Patients
NZ268110A (en) Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
HU905683D0 (en) The treatment of drug dependence by using sertraline
MX9602793A (en) The use of sertraline to treat post myocardial infarction patients.
AU7230894A (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
MX9701528A (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)